CN116406360A - 杂环glp-1激动剂 - Google Patents

杂环glp-1激动剂 Download PDF

Info

Publication number
CN116406360A
CN116406360A CN202180071640.XA CN202180071640A CN116406360A CN 116406360 A CN116406360 A CN 116406360A CN 202180071640 A CN202180071640 A CN 202180071640A CN 116406360 A CN116406360 A CN 116406360A
Authority
CN
China
Prior art keywords
compound
ring
compound according
alkyl
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180071640.XA
Other languages
English (en)
Chinese (zh)
Inventor
孟庆华
邢唯强
张海珍
林熹晨
雷晖
A·詹宁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gashubrum Biology
Original Assignee
Gashubrum Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gashubrum Biology filed Critical Gashubrum Biology
Publication of CN116406360A publication Critical patent/CN116406360A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180071640.XA 2020-08-28 2021-08-27 杂环glp-1激动剂 Pending CN116406360A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020112149 2020-08-28
CNPCT/CN2020/112149 2020-08-28
PCT/CN2021/115064 WO2022042691A1 (en) 2020-08-28 2021-08-27 Heterocyclic glp-1 agonists

Publications (1)

Publication Number Publication Date
CN116406360A true CN116406360A (zh) 2023-07-07

Family

ID=80354684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180071640.XA Pending CN116406360A (zh) 2020-08-28 2021-08-27 杂环glp-1激动剂

Country Status (5)

Country Link
US (4) US11926626B2 (https=)
EP (1) EP4204415A4 (https=)
JP (1) JP2023538949A (https=)
CN (1) CN116406360A (https=)
WO (1) WO2022042691A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118598864A (zh) * 2024-03-06 2024-09-06 中国药科大学 一种芳基苯并咪唑类化合物、其药物组合物和应用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
EP4204415A4 (en) * 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CR20230330A (es) * 2021-01-28 2023-11-15 Carmot Therapeutics Inc Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
MX2024004131A (es) 2021-10-05 2024-04-22 Astrazeneca Ab Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20250115612A1 (en) 2021-10-05 2025-04-10 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
CN117362282B (zh) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
US20260028332A1 (en) * 2022-07-18 2026-01-29 Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd Polymorphic form of glp-1r agonist, preparation method therefor and use thereof
CN117417329A (zh) * 2022-07-18 2024-01-19 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂的多晶型物及其制备方法与用途
CN117417330A (zh) * 2022-07-18 2024-01-19 德睿智药(苏州)新药研发有限公司 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途
EP4562006A1 (en) * 2022-07-27 2025-06-04 Carmot Therapeutics, Inc. N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
KR20250085816A (ko) 2022-11-16 2025-06-12 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
CN118319871B (zh) * 2024-04-19 2025-08-05 鲁南新时代生物技术有限公司 一种司美格鲁肽药物组合物
WO2025264849A1 (en) * 2024-06-20 2025-12-26 Biolexis Therapeutics, Inc. Glp-1 agonists and methods of use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280933A1 (en) * 2006-07-25 2008-11-13 Ivan Efremov Benzimidazolyl compounds
US20180170908A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. GLP-1 Agonists and Uses Thereof
CN108430998A (zh) * 2016-09-28 2018-08-21 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2019239319A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2020234726A1 (en) * 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2021096284A1 (ko) * 2019-11-15 2021-05-20 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
CN117043154A (zh) * 2021-01-28 2023-11-10 卡莫特医疗有限公司 Gpcr受体激动剂、包含其的药物组合物以及它们的使用方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006799A (es) * 2004-12-23 2007-07-20 Basf Ag Mezclas fungicidas.
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
EP3953344A4 (en) 2019-04-12 2023-08-09 Qilu Regor Therapeutics Inc. GLP-IR AGONISTS AND THEIR USES
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
CN114761395B (zh) 2019-12-02 2024-11-15 现代药品株式会社 Glp-1受体激动剂
ES3016132T3 (en) 2020-01-29 2025-05-08 Gilead Sciences Inc Glp-1r modulating compounds
JP7836762B2 (ja) 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
IL296336A (en) 2020-03-18 2022-11-01 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
CN113493447B (zh) 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
MX2022015026A (es) 2020-06-04 2023-01-04 Hangzhou Sciwind Biosciences Co Ltd Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.
CN115697338B (zh) 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN117645601A (zh) 2020-06-10 2024-03-05 重庆康丁医药技术有限公司 一种具有心血管益处的glp-1小分子
CN113801136B (zh) 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN113816948B (zh) 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) 2020-06-19 2025-01-14 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113831337B (zh) 2020-06-24 2023-03-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
WO2022031994A1 (en) 2020-08-06 2022-02-10 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CA3192601A1 (en) 2020-08-21 2022-02-24 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4204415A4 (en) 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CA3188891A1 (en) 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
WO2022068772A1 (zh) 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
EP4229050A4 (en) 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20240083886A1 (en) 2020-10-13 2024-03-14 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
CN114591296A (zh) 2020-12-02 2022-06-07 海思科医药集团股份有限公司 一种glp-1r激动剂及其在医药上的应用
CN114591308B (zh) 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
CN114634510B (zh) 2020-12-16 2025-11-04 杭州中美华东制药有限公司 咪唑并吡啶衍生物及其用途
WO2022135572A1 (zh) 2020-12-25 2022-06-30 四川海思科制药有限公司 一种五并五元环衍生物及其在医药上的应用
CN114763352A (zh) 2021-01-15 2022-07-19 海思科医药集团股份有限公司 一种glp-1受体激动剂及其在医药上的应用
CR20230330A (es) * 2021-01-28 2023-11-15 Carmot Therapeutics Inc Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
CN114907351A (zh) 2021-02-07 2022-08-16 杭州中美华东制药有限公司 三环类glp-1受体激动剂及其用途
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117222631A (zh) 2021-03-24 2023-12-12 诚益生物(美国)公司 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法
WO2022216094A1 (ko) 2021-04-08 2022-10-13 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CN115594669B (zh) 2021-07-09 2024-11-05 深圳信立泰药业股份有限公司 一种并环类衍生物及其制备方法和医药用途
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
CN114716423A (zh) 2022-05-20 2022-07-08 中国科学院上海药物研究所 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280933A1 (en) * 2006-07-25 2008-11-13 Ivan Efremov Benzimidazolyl compounds
CN108430998A (zh) * 2016-09-28 2018-08-21 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
US20180170908A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. GLP-1 Agonists and Uses Thereof
CN110325530A (zh) * 2016-12-16 2019-10-11 辉瑞大药厂 Glp-1受体激动剂及其用途
WO2019239319A1 (en) * 2018-06-13 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2020234726A1 (en) * 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2021096284A1 (ko) * 2019-11-15 2021-05-20 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
CN114728940A (zh) * 2019-11-15 2022-07-08 日东制药株式会社 Glp-1受体激动剂及其用途
CN117043154A (zh) * 2021-01-28 2023-11-10 卡莫特医疗有限公司 Gpcr受体激动剂、包含其的药物组合物以及它们的使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118598864A (zh) * 2024-03-06 2024-09-06 中国药科大学 一种芳基苯并咪唑类化合物、其药物组合物和应用

Also Published As

Publication number Publication date
US20230107793A1 (en) 2023-04-06
US12221442B2 (en) 2025-02-11
US20240246962A1 (en) 2024-07-25
WO2022042691A1 (en) 2022-03-03
US20250115606A1 (en) 2025-04-10
EP4204415A4 (en) 2025-03-26
EP4204415A1 (en) 2023-07-05
US11926626B2 (en) 2024-03-12
JP2023538949A (ja) 2023-09-12
US20230071840A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
CN116406360A (zh) 杂环glp-1激动剂
US11897851B2 (en) Heterocyclic GLP-1 agonists
JP2023546054A (ja) ヘテロ環ｇｌｐ－１アゴニスト
CN116368140A (zh) 杂环glp-1激动剂
CN116615430A (zh) 杂环glp-1激动剂
EP4496797A1 (en) 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CN119343343A (zh) 杂环glp-1激动剂
CN119072474A (zh) 杂环glp-1激动剂
CN119255988A (zh) 杂环glp-1激动剂
US20250051355A1 (en) Compounds, compositions, and methods
HK40122516A (zh) 作为glp-1激动剂用於糖尿病治疗的5，8-二氢-1，7-萘啶衍生物
HK40122544A (zh) 杂环glp-1激动剂
HK40119249A (zh) 杂环glp-1激动剂
HK40096299A (zh) 杂环glp-1激动剂
WO2025171340A1 (en) The treatment of calcitonin- and/or amylin-receptor associated conditions
US20260042760A1 (en) Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
HK40120672A (zh) 杂环glp-1激动剂
HK40121127A (zh) 杂环glp-1激动剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination